A personalized mRNA cancer vaccine developed by Moderna and Merck significantly reduces melanoma recurrence risks, according to landmark Phase 3 clinical trial results.

A phase 3 clinical trial evaluating Moderna and Merck's personalized mRNA skin cancer vaccine has met its primary goals in delaying recurrence.

Moderna's personalized mRNA cancer vaccine Intismeran met its primary endpoint in a late-stage trial combined with Merck's Keytruda, sparking a major market rally.